Repligen beats estimates as bioprocessing recovery gains traction

Repligen (NASDAQ:RGEN) reported fourth-quarter results that surpassed analyst forecasts, providing fresh evidence that the bioprocessing industry is successfully moving past its post-pandemic destocking phase.

The company posted quarterly revenue of $197.9 million, an 18% increase year-over-year, beating the consensus estimate of $192.2 million.

Growth was led by the Analytics and Proteins franchises, which helped drive a 14% increase in organic revenue.

Net income for the period reached $13.3 million, or $0.23 per share.

On an adjusted basis, earnings were $0.49 per share, comfortably ahead of the $0.44 per share anticipated by analysts.

For the full year 2025, Repligen generated $738.3 million in revenue and $48.9 million in net income.

Despite the quarterly beat, Repligen issued a 2026 profit forecast that fell slightly short of market expectations.

The company projected full-year adjusted earnings between $1.93 and $2.01 per share, compared to a consensus estimate of $2.07.

Revenue for 2026 is expected to range from $810 million to $840 million, representing reported growth of 10% to 14%.